Dopler, A., Stibitzky, S., Hevey, R., Mannes, M., Guariento, M., Höchsmann, B., Schrezenmeier, H., Ricklin, D. and Schmidt, C. Q. (2021) “Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces”, Frontiers in immunology, 12, p. 615748. doi: 10.3389/fimmu.2021.615748.   
Hughes, S., Gumas, J., Lee, R., Rumano, M., Berger, N., Gautam, A. K., Sfyroera, G., Chan, A. L., Gnanaguru, G., Connor, K. M., Kim, B. J., Dunaief, J. L., Ricklin, D., Hajishengallis, G., Yancopoulou, D., Reis, E. S., Mastellos, D. C. and Lambris, J. D. (2020) “Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates”, Clinical Immunology. Elsevier, 214, p. 108391. doi: 10.1016/j.clim.2020.108391.   edoc
Olcina, M. M., Kim, R. K., Balanis, N. G., Li, C. G., von Eyben, R., Graeber, T. G., Ricklin, D., Stucki, M. and Giaccia, A. J. (2020) “Intracellular C4BPA Levels Regulate NF-κB-Dependent Apoptosis”, iScience. Cell Press, 23(10), p. 101594. doi: 10.1016/j.isci.2020.101594.   edoc
Baas, I., Delvasto-Nuñez, L., Ligthart, P., Brouwer, C., Folman, C., Reis, E. S., Ricklin, D., Lambris, J. D., Wouters, D., de Haas, M., Jongerius, I. and Zeerleder, S. S. (2020) “Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells”, Haematologica. Ferrata Storti Foundation, 105(2), pp. e57-e60. doi: 10.3324/haematol.2019.216028.   edoc | Open Access
Hevey, R., Pouw, R. B., Harris, C. and Ricklin, D. (2020) “Sweet Turning Bitter: Carbohydrate Sensing of Complement in Host Defence and Disease”, British journal of pharmacology, p. Online ahead of print. doi: 10.1111/bph.15307.   
Kroezen, B., Conti, G., Girardi, B., Cramer, J., Jiang, X., Rabbani, S., Müller, J., Kokot, M., Luisoni, E., Ricklin, D., Schwardt, O. and Ernst, B. (2020) “A Potent Mimetic of the Siglec-8 Ligand 6’-Sulfo-Sialyl Lewisx”, ChemMedChem, 15, pp. 1706–1719. doi: 10.1002/cmdc.202000417.   
Epper, B. (2019) “Dossier ‘Wirkstoffe’ - Vom Molekül zum Medikament”, Drogistenstern, 12 January, pp. 6–16.   edoc
van Griensven, M., Ricklin, D., Denk, S., Halbgebauer, R., Braun, C. K., Schultze, A., Hönes, F., Koutsogiannaki, S., Primikyri, A., Reis, E., Messerer, D., Hafner, S., Radermacher, P., Biglarnia, A.-R., Resuello, R. R. G., Tuplano, J. V., Mayer, B., Nilsson, K., Nilsson, B., Lambris, J. D. and Huber-Lang, M. (2019) “Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock”, Shock. Lippincott, Williams & Wilkins, 51(1), pp. 78–87. doi: 10.1097/SHK.0000000000001127.   edoc
Mastellos, D. C., Blom, A. M., Connolly, E. S., Daha, M. R., Geisbrecht, B. V., Ghebrehiwet, B., Gros, P., Hajishengallis, G., Holers, V. M., Huber-Lang, M., Kinoshita, T., Mollnes, T. E., Montgomery, R. A., Morgan, B. P., Nilsson, B., Pio, R., Ricklin, D., Risitano, A. M., Taylor, R. P., Mantovani, A., Ioannidis, J. P. A. and Lambris, J. D. (2019) “’Stealth’ corporate innovation: an emerging threat for therapeutic drug development”, Nature immunology, 20(11), pp. 1409–1413. doi: 10.1038/s41590-019-0503-1.   edoc
Mastellos, D. C., Ricklin, D. and Lambris, J. D. (2019) “Clinical promise of next-generation complement therapeutics”, Nature reviews. Drug discovery, 18(9), pp. 707–729. doi: 10.1038/s41573-019-0031-6.   edoc
Lombardi, E., Matte, A., Risitano, A. M., Ricklin, D., Lambris, J. D., De Zanet, D., Jokiranta, S. T., Martinelli, N., Scambi, C., Salvagno, G., Bisoffi, Z., Colato, C., Siciliano, A., Bortolami, O., Mazzuccato, M., Zorzi, F., De Marco, L. and De Franceschi, L. (2019) “Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule”, Haematologica, 104(5), pp. 919–928. doi: 10.3324/haematol.2018.198622.   edoc
Ricklin, D., Mastellos, D. C. and Lambris, J. D. (2019) “Therapeutic targeting of the complement system ”, Nature Reviews. Drug Discovery. Nature Publishing Group. doi: 10.1038/s41573-019-0055-y.   
Yuan, X., Yang, M., Chen, X., Zhang, X., Sukhadia, S., Musolino, N., Bao, H., Chen, T., Xu, C., Wang, Q., Santoro, S., Ricklin, D., Hu, J., Lin, R., Yang, W., Li, Z., Qin, W., Zhao, A., Scholler, N. and Coukos, G. (2018) “Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy”, Cancer immunology, immunotherapy : CII, 67(2), pp. 329–339. doi: 10.1007/s00262-017-2101-0.   edoc
Devaurs, D., Papanastasiou, M., Antunes, D. A., Abella, J. R., Moll, M., Ricklin, D., Lambris, J. D. and Kavraki, L. E. (2018) “Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling”, International journal of computational biology and drug design, 11(1-2), pp. 90–113. doi: 10.1504/IJCBDD.2018.090834.   edoc
Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R. and Ricklin, D. (2018) “Developments in anti-complement therapy; from disease to clinical trial”, Molecular immunology. Elsevier, 102, pp. 89–119. doi: 10.1016/j.molimm.2018.06.008.   edoc
Ricklin, D., Mastellos, D. C., Reis, E. S. and Lambris, J. D. (2018) “The renaissance of complement therapeutics”, Nature Reviews Nephrology . Nature Publishing Group, 14(1), pp. 26–47. doi: 10.1038/nrneph.2017.156.   edoc
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A. and Lambris, J. D. (2018) “Complement in cancer: untangling an intricate relationship”, Nature reviews. Immunology. Springer Nature, 18(1), pp. 5–18. doi: 10.1038/nri.2017.97.   edoc | Open Access
Blatt, A. Z., Saggu, G., Cortes, C., Herbert, A. P., Kavanagh, D., Ricklin, D., Lambris, J. D. and Ferreira, V. P. (2017) “Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation”, Frontiers in Immunology. Frontiers Media, 8, p. 1586. doi: 10.3389/fimmu.2017.01586.   edoc | Open Access
Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D. and Lambris, J. D. (2017) “Novel mechanisms and functions of complement”, Nature Immunology. Nature Publishing Group, 18(12), pp. 1288–1298. doi: 10.1038/ni.3858.   edoc
Wang, H., Ricklin, D. and Lambris, J. D. (2017) “Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4”, Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences, 114(41), pp. 10948–10953. doi: 10.1073/pnas.1707364114.   edoc
Ricklin, D., Barratt-Due, A. and Mollnes, T. E. (2017) “Complement in clinical medicine: Clinical trials, case reports and therapy monitoring”, Molecular Immunology. Elsevier, 89, pp. 10–21. doi: 10.1016/j.molimm.2017.05.013.   edoc | Open Access
Primikyri, A., Papanastasiou, M., Sarigiannis, Y., Koutsogiannaki, S., Reis, E. S., Tuplano, J. V., Resuello, R. R. G., Nilsson, B., Ricklin, D. and Lambris, J. D. (2017) “Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS”, Journal of Chromatography B. Elsevier, 1041-1042, pp. 19–26. doi: 10.1016/j.jchromb.2016.12.004.   edoc
Yuan, X., Yang, M., Chen, X., Zhang, X., Sukhadia, S., Musolino, N., Bao, H., Chen, T., Xu, C., Wang, Q., Santoro, S., Ricklin, D., Hu, J., Lin, R., Yang, W., Li, Z., Qin, W. and Zhao, A. (2017) “Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy”, Cancer Immunology, Immunotherapy. Springer, 66(3), pp. 367–378. doi: 10.1007/s00262-016-1937-z.   edoc
Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J. and Lambris, J. D. (2017) “Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery”, Trends in Immunology. Elsevier, 38(6), pp. 383–394. doi: 10.1016/   edoc
Xue, X., Wu, J., Ricklin, D., Forneris, F., Di Crescenzio, P., Schmidt, C. Q., Granneman, J., Sharp, T. H., Lambris, J. D. and Gros, P. (2017) “Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses”, Nature Structural and Molecular Biology. Nature Publishing Group , 24, pp. 643–651. doi: 10.1038/nsmb.3427.   edoc
Harder, M. J., Kuhn, N., Schrezenmeier, H., Höchsmann, B., von Zabern, I., Weinstock, C., Simmet, T., Ricklin, D., Lambris, J. D., Skerra, A., Anliker, M. and Schmidt, C. Q. (2017) “Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation”, Blood. American Society of Hematology, 129(8), pp. 970–980. doi: 10.1182/blood-2016-08-732800.   edoc
Devaurs, D., Antunes, D. A., Papanastasiou, M., Moll, M., Ricklin, D., Lambris, J. D. and Kavraki, L. E. (2017) “Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data”, Frontiers in Molecular Biosciences. Frontiers Media, 4, p. 13. doi: 10.3389/fmolb.2017.00013.   edoc
Papanastasiou, M., Koutsogiannaki, S., Sarigiannis, Y., Geisbrecht, B. V., Ricklin, D. and Lambris, J. D. (2017) “Structural Implications for the Formation and Function of the Complement Effector Protein iC3b”, Journal of immunology (Baltimore, Md. : 1950). The American Association of Immunologists, Inc, 198(8), pp. 3326–3335. doi: 10.4049/jimmunol.1601864.   edoc
Schmidt, C. Q., Lambris, J. D. and Ricklin, D. (2016) “Protection of host cells by complement regulators”, Immunological Reviews. Wiley-Blackwell Publishing, 274(1), pp. 152–171. doi: 10.1111/imr.12475.   edoc
Ricklin, D. and Lambris, J. D. (2016) “Preformed mediators of defense-Gatekeepers enter the spotlight”, Immunological Reviews. Wiley-Blackwell Publishing, 274(1), pp. 5–8. doi: 10.1111/imr.12497.   edoc
Ricklin, D., Reis, E. S., Mastellos, D. C., Gros, P. and Lambris, J. D. (2016) “Complement component C3 - The ‘Swiss Army Knife’ of innate immunity and host defense”, Immunological Reviews . Wiley-Blackwell Publishing, 274(1), pp. 33–58. doi: 10.1111/imr.12500.   edoc
Ricklin, D. (2005) Surface plasmon resonance applications in drug discovery : with an emphasis on small molecule and low affinity systems. doi: 10.5451/unibas-003733597.   edoc | Open Access